SD-2301 is a potent and selective PROTAC-based STAT3 degrader that targets the VHL–cullin 2 complex, enhancing dendritic cell function and anti-tumor immunity. It synergizes with anti-PD-L1 therapy to robustly suppress tumor growth in vivo.